Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer

Qingyuan Zhang, Tao Wang, Cuizhi Geng, Yue Zhang, Jinwen Zhang, Zhiqiang Ning, Zefei Jiang, Qingyuan Zhang, Tao Wang, Cuizhi Geng, Yue Zhang, Jinwen Zhang, Zhiqiang Ning, Zefei Jiang

Abstract

Objective: The recurrence or progression under endocrine therapy in hormone receptor-positive (HR+) advanced breast cancer (ABC) remained a critical clinical challenge. Chidamide is an oral subtype-selective histone deacetylase (HDAC) inhibitor with multiple functions in tumor growth inhibition and microenvironment modulation via epigenetic reprogramming. The purpose of this study was to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of chidamide in combination with exemestane in HR+ ABC patients.

Methods: Eligible patients were postmenopausal women with HR+ ABC recurrent or progressed to at least one endocrine therapy. Blood samples were obtained in the run-in period and the first day of combination treatment for PK analysis. In combination treatment, patients were given exemestane 25 mg daily and chidamide 30 mg twice a week (BIW) until progression of disease or intolerable toxicities. A treatment cycle was defined as 4 weeks. Safety, PK parameters, and preliminary efficacy were evaluated.

Results: A total of 20 patients were enrolled between July and December, 2015. The median number of treatments cycle was 5.2 (20.8 weeks) with 2 patients still on treatment at the data cut-off date of October, 2017. The treatment-related adverse events (AE) ≥ grade 3 in more than 2 patients were neutropenia (35%), thrombocytopenia (30%), and leucopenia (20%). The plasma exposure of exemestane was consistent in the presence or absence of chidamide. A slight increase in chidamide exposure was noted in the presence of exemestane, probably due to the inter- and intra-patient variations. The best response in 16 evaluable patients was assessed by Response Evaluation Criteria in Solid Tumors (RECIST), including 4 patients with partial response, 10 patients with stable disease. The median progression-free survival (PFS) was 7.6 months.

Conclusions: The combination of chidamide with exemestane was generally well tolerated with promising preliminary efficacy in HR+ ABC patients. The overall results from this study encourage further pivotal trial in this patient population.

Keywords: Advanced breast cancer; chidamide; exemestane; hormone receptor-positive.

Figures

1
1
Mean plasma concentration-time curves of exemestane (A) and chidamide (B) alone or in combination treatment.
2
2
Kaplan-Meier estimates of progression-free survival (PFS) probability.

References

    1. Anderson WF, Chatterjee N, Ershler WB, et al Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76:27–36. doi: 10.1023/A:1020299707510.
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84. doi: 10.1016/S0140-6736(11)60993-8.
    1. Osborne CK, Schiff R Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–47. doi: 10.1146/annurev-med-070909-182917.
    1. DeMichele A, Chodosh LA " Braking” the cycle of resistance in endocrine therapy for breast cancer. Clin Cancer Res. 2015;21:4999–5001. doi: 10.1158/1078-0432.CCR-15-1146.
    1. Falahi F, van Kruchten M, Martinet N, et al Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. Breast Cancer Res. 2014;16:412. doi: 10.1186/s13058-014-0412-z.
    1. Li Y, Seto E HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6:pii: a026831. doi: 10.1101/cshperspect.a026831.
    1. Sharma D, Saxena NK, Davidson NE, et al Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 2006;66:6370–8. doi: 10.1158/0008-5472.CAN-06-0402.
    1. Sabnis GJ, Goloubeva O, Chumsri S, et al Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 2011;71:1893–903. doi: 10.1158/0008-5472.CAN-10-2458.
    1. Sabnis GJ, Goloubeva OG, Kazi AA, et al HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Mol Cancer Ther. 2013;12:2804–16. doi: 10.1158/1535-7163.MCT-13-0345.
    1. Yardley DA, Ismail-Khan RR, Melichar B, et al Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31:2128–35. doi: 10.1200/JCO.2012.43.7251.
    1. Pan DS, Yang QJ, Fu X, et al Discovery of an orally active subtype-selective HDAC Inhibitor, chidamide, as an epigenetic modulator for cancer treatment. Med. Chem. Commun. 2014;5:1789–96. doi: 10.1039/C4MD00350K.
    1. Shi Y, Dong M, Hong X, et al Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26:1766–71. doi: 10.1093/annonc/mdv237.
    1. Ning ZQ, Li ZB, Newman MJ, et al Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69:901–9. doi: 10.1007/s00280-011-1766-x.
    1. Yao Y, Zhou J, Wang L, et al Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS One. 2013;8:e70522. doi: 10.1371/journal.pone.0070522.
    1. Falkenberg KJ, Johnstone RW Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13:673–91. doi: 10.1038/nrd4360.
    1. Pili R, Quinn DI, Hammers HJ, et al Immunomodulation by entinostat in renal cell carcinoma patients receiving high-dose interleukin 2: A multicenter, single-arm, phase I/II trial (NCI-CTEP#7870) Clin Cancer Res. 2017;23:7199–208. doi: 10.1158/1078-0432.CCR-17-1178.
    1. Zhou Y, Wang Y, Zhang K, et al Reverse effect of chidamide on endocrine resistance in estrogen receptor-positive breast cancer. Journal of Shenzhen University Science and Engineering. 2018;35:339–44. doi: 10.3724/SP.J.1249.2018.04000.
    1. Hertz DL, Kidwell KM, Seewald NJ, et al Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J. 2017;17:521–7. doi: 10.1038/tpj.2016.60.
    1. Hu X, Wang L, Lin L, et al A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Chin J Cancer Res. 2016;28:444–51. doi: 10.21147/j.issn.1000-9604.2016.04.08.
    1. Munster PN, Troso-Sandoval T, Rosen N, et al The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001;61:8492–7.
    1. Tan WW, Allred JB, Moreno-Aspitia A, et al Phase I study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients. Clin Breast Cancer. 2016;16:82–6. doi: 10.1016/j.clbc.2015.11.003.
    1. Shi Y, Jia B, Xu W, et al Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10:69. doi: 10.1186/s13045-017-0439-6.
    1. Paridaens RJ, Dirix LY, Beex LV, et al Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:4883–90. doi: 10.1200/JCO.2007.14.4659.
    1. Dong M, Ning ZQ, Xing PY, et al Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol. 2012;69:1413–22. doi: 10.1007/s00280-012-1847-5.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren